Post-earnings recap
Reported
Tue, May 14, 2019
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
75%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
Aurinia Pharmaceuticals reported a loss of $0.14 per share, but the stock saw a slight increase of 0.33% following the announcement. The lack of revenue figures and management commentary leaves investors without additional context for the results. The market's positive reaction may suggest some investor confidence despite the EPS miss.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.14 | N/A | — |
| Revenue | — | N/A | — |
No transcript is on record, and the analysis is based solely on numerical results.